Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,116 recruiting studies in this area right now.
By phase
- Not applicable9,488
- Phase 24,391
- Phase 12,658
- Phase 1/Phase 21,647
- Phase 31,391
- Phase 2/Phase 3281
- Phase 4260
Top conditions
- Breast Cancer1,192
- Prostate Cancer644
- Cancer632
- Colorectal Cancer478
- Lung Cancer415
- Ovarian Cancer336
- Multiple Myeloma328
- Pancreatic Cancer287
- Gastric Cancer283
- Acute Myeloid Leukemia279
- Hepatocellular Carcinoma256
- Solid Tumor245
- Advanced Solid Tumor235
- Head and Neck Cancer225
- Cervical Cancer223
- Endometrial Cancer206
- Advanced Solid Tumors199
- Esophageal Cancer189
Leading sponsors
- M.D. Anderson Cancer Center453
- Fudan University303
- National Cancer Institute (NCI)292
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University273
- Mayo Clinic237
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences140
- City of Hope Medical Center140
- AstraZeneca134
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,404
- Texas636
- Arizona513
- Florida431
- Alabama424
- New York407
- Massachusetts340
- Maryland332
- New Jersey269
- Pennsylvania234
Recruiting studies20,116 total
- NCT03131531Recruiting
Lymphoid cancer registry for lymphoma and myeloma patients
This study is a cancer registry that collects information from people with lymphoma, Hodgkin disease, or myeloma. It helps researchers understand these cancers better by using real-world patient data.
BergamoAges 18 years+ - NCT04597294RecruitingPhase 3
Preventive pre-op HIPEC for advanced stomach cancer
This Phase 3 trial studies whether adding a heated chemotherapy procedure during surgery (HIPEC) before the main cancer treatment can lower the chance that stomach cancer returns in the belly. It is for people with advanced stomach cancer who are at higher risk of cancer coming back in the peritoneum (the lining of the abdomen).
Krakow, Lesser Poland VoivodshipAges 18–75 - NCT05085028RecruitingPhase 3
Lower-dose pembrolizumab for lung cancer after 6 months
This trial studies whether giving pembrolizumab less often can work just as well for advanced non-small cell lung cancer after you’ve already had 6 months of treatment and are still benefiting. It may help reduce how often you need treatment while keeping cancer control.
BournemouthAges 18 years+ - NCT05789901Recruiting
Using a Facebook chatbot to share health information
This study tests whether a Facebook Messenger chatbot can provide helpful health information for different conditions. You may help researchers check if people can use the chatbot and understand the information.
Montreal, QuebecAges 14 years+ - NCT06194734RecruitingPhase 3
KC1036 vs. chemo for advanced esophageal cancer
This study compares a new drug, KC1036, to standard chemotherapy options for people with advanced esophageal squamous cell cancer that has progressed after immunotherapy and at least one chemo. It aims to see if KC1036 works better or has fewer side effects.
BeijingAges 18–75 - NCT06248944Recruiting
Italian registry for head and neck cancers
This registry collects information from Italian hospitals about people with head and neck cancers. By joining, you help doctors better understand the disease and improve future treatments.
CandioloAges 18 years+ - NCT06297512RecruitingPhase 2
Testing chemotherapy after radiation for young patients with glioblastoma
This trial tests whether a type of chemotherapy called anthracycline can help young patients with glioblastoma when given after radiation therapy. It aims to see if this treatment improves outcomes for patients aged 3 to 30.
FlorenceAges 3–30 - NCT05116475RecruitingPhase 3
New prostate cancer trial adding darolutamide to standard treatment
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
Chambray-lès-ToursAges 18–120 - NCT04455282Recruiting
Blood test-guided surgery for gastroesophageal cancer
This trial studies blood-based biomarkers to help doctors choose the best individualized surgical treatment for gastroesophageal junction adenocarcinoma. If you qualify, you’ll get standard care plus additional testing to see whether the blood results can guide surgery more precisely.
Cologne, North Rhine-WestphaliaAges 18 years+ - NCT06053099Recruiting
Study of osimertinib after surgery for EGFR-mutated lung cancer
This trial collects data from people with early-stage lung cancer that has a common EGFR mutation. After complete surgical removal of the tumor, participants take osimertinib for 3 years and are followed regularly to see how well the treatment works and why resistance might develop.
AngersAges 18 years+ - NCT05975749RecruitingPhase 2
Trastuzumab, serplulimab, and chemo after stomach cancer surgery
This Phase 2 study looks at whether adding serplulimab to trastuzumab and chemotherapy after surgery can lower the chance of stomach cancer coming back. It is for people with HER2-positive stage II–III stomach adenocarcinoma who have already had curative surgery with lymph node removal.
Shanghai, Shanghai MunicipalityAges 20–80 - NCT05346367Recruiting
Targeted brain radiation to improve treatment benefit and limit side effects
This study tests a more targeted form of stereotactic (precise) brain radiation for people with brain metastases from large cell cancer. It aims to improve the balance between effectiveness and side effects by carefully focusing where the radiation goes.
Leidschendam, South HollandAges 18 years+ - NCT06187597RecruitingPhase 2
Toripalimab after chemoradiation for older esophageal cancer
This study tests whether adding a drug called toripalimab after standard chemoradiation can help older adults with esophageal cancer. The goal is to see if this treatment can keep the cancer from coming back after initial therapy.
Guangzhou, GuangdongAges 70–85 - NCT06261125RecruitingPhase 2
SBRT plus immunotherapy and targeted drug for liver cancer
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
Guangzhou, GuangdongAges 18–75 - NCT06219980RecruitingPhase 2
Radiation and immunotherapy before surgery for oral cancer
This trial tests combining radiation therapy with immunotherapy and chemotherapy before surgery for advanced oral or throat cancer. The goal is to see if this approach can shrink the tumor and improve treatment outcomes.
Guangzhou, GuangdongAges 18–70 - NCT06202261RecruitingPhase 1/Phase 2
Study of TQB2930 for breast cancer that has returned or spread
This trial tests a new drug called TQB2930 alone or with other treatments for people with recurrent or metastatic breast cancer. It may help if you have a type of breast cancer called HER2-positive and have not had many prior treatments for advanced disease.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06598046RecruitingPhase 2
Utidelone and Capecitabine for triple-negative breast cancer brain metastases
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
Zhengzhou, HenanAges 18 years+ - NCT06307314Recruiting
Can SAA1 predict mouth sores from radiation therapy?
This study is looking at a blood marker called SAA1 to see if it can predict how severe mouth sores (oral mucositis) will be after radiation therapy. If you have head and neck cancer and are about to get radiation, this trial may help answer questions about side effects.
Guangzhou, GuangdongAges 18 years+ - NCT06307249RecruitingPhase 1
Precision therapy for solid tumors targeting CDK4/6 and VEGF
This trial tests a combination of two targeted drugs for advanced solid tumors like colorectal, lung, breast, and genitourinary cancers. The goal is to see if blocking certain proteins and a long RNA molecule can slow tumor growth.
Tripoli, North LebanonAges 18 years+ - NCT06306846RecruitingPhase 2
Radiation and immunotherapy before surgery for head and neck cancer
This study tests giving a short course of targeted radiation (SBRT) along with immunotherapy and a targeted drug before surgery for advanced head and neck cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
Hangzhou, ZhejiangAges 18–70 - NCT06305910RecruitingPhase 1
Vaccine immunotherapy for recurrent brain tumors or newly diagnosed DIPG
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
Minneapolis, MinnesotaAges 2–25 - NCT06305832RecruitingPhase 2
Salvage radiation plus hormone therapy with or without rezvilutamide for rising PSA
This trial tests whether adding a new oral hormone blocker (rezvilutamide) to standard salvage radiation and hormone therapy can better control prostate cancer that has come back (rising PSA) after surgery.
Nanjing, JiangsuAges 40 years+ - NCT06308354Recruiting
Colorectal cancer data study at Xijing Hospital
This study collects and reviews medical records from patients diagnosed with colorectal adenocarcinoma at Xijing Hospital between 2013 and 2023. The goal is to build a dataset for future research—no new treatments or procedures are being tested.
Xi'an, ShaanxiAges 18–100 - NCT04965077RecruitingPhase 1
First study of MIL97 for advanced solid tumors
This Phase 1 trial tests MIL97, a new treatment, in adults with advanced solid cancers that have come back or cannot be removed. The goal is to find a safe dose and see how the cancer responds.
Beijing, Beijing MunicipalityAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,116 recruiting oncology studies from the U.S. registry right now, out of 29,780 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.